Arbutus Biopharma
ABUS
48 hedge funds and large institutions have $100M invested in Arbutus Biopharma in 2014 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 6 increasing their positions, 18 reducing their positions, and 12 closing their positions.
75% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 12
23% more funds holding
Funds holding: 39 → 48 (+9)
3% more capital invested
Capital invested by funds: $97.6M → $100M (+$2.77M)
39% less call options, than puts
Call options by funds: $11.6M | Put options by funds: $19.1M
67% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 18
Top Buyers
Top Sellers
ABUS Hedge Fund Activity: Q3 2014 in Review
48 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2014, worth a combined $100M — up 2.8% from $97.6M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ABUS positions and 12 closed out — a net gain of 9 holders — while 6 added to existing stakes and 18 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $6.82M. The largest seller was Franklin Resources, cutting an estimated $20M.
- 48 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2014, up from 39 in Q2 2014.
- Funds reported $100M of Arbutus Biopharma stock for Q3 2014, up 2.8% quarter-over-quarter.
- 21 funds opened new Arbutus Biopharma positions in Q3 2014 and 12 closed out, a net change of +9 holders.
- The largest Arbutus Biopharma buyer in Q3 2014 was Morgan Stanley, an estimated $6.82M added.
- The largest Arbutus Biopharma seller in Q3 2014 was Franklin Resources, an estimated $20M sold.
Based on aggregated 13F filings for Q3 2014.